Key facts
- This page summarizes Tai Sandi See's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2025, 16:55.
Tai Sandi See - 07 Jan 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- LXEO
- Reported as of
- 07 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2025, 16:55:07 UTC
- Prior SEC filing
- 06 Feb 2024
- Next SEC filing
- 21 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Youjin Choi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tai Sandi See filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 10 Jan 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXEO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +38,750
- Change %
- +233%
- Price
- $0.000000
- Shares after
- 55,375
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXEO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +77,500
- Change %
- Price
- $0.000000
- Shares after
- 77,500
- Date
- 07 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 77,500
- Exercise price
- $7.33
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
Footnote F2
The reported securities are RSUs.
Footnote F3
25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.